Back to search

Champions Oncology Uk Limited

06861239

active
Private Limited Company
england wales
Companies House
Health Score
70 / 100

Some Concerns

30/30
Filing
0/30
Financial
40/40
Risk
  • Current liabilities exceed current assets (-10)
  • Going concern doubt noted in accounts (-10)

Details

SUITE 1, 7TH FLOOR, LONDON, SW1H 0BL
Incorporated 27/03/2009

Compliance

Last accounts

30/04/2025

medium

Next accounts due

31/01/2027

On track

Confirmation statement

Last: 27/03/2026

Due 10/04/2027

On track

Industry

72110
Research and experimental development on biotechnology

Officers

Dr David Sidransky

director · Since 08/02/2010

NONE

AMERICAN · UNITED STATES · Age 66

Vistra Company Secretaries Limited

secretary · Since 27/03/2010

BRITISH

Also on 530 other boards

Joel Ackerman

director · Since 06/04/2011

CEO

AMERICAN · UNITED STATES · Age 61

Persons with Significant Control

Champions Oncology, Inc.

75–100% shares
75–100% votes
Appoint directors

One University Plaza, Hackensack, New Jersey, 07601

Reg: 2063377 · State Of Delaware · Corporation

Notified 06/04/2016

CompanyRankvs 1670+ SIC 72110 peers
37

Financial strength49th percentile among SIC peers · 12/25
Employees22th percentile among SIC peers · 3/15
LiquidityCurrent ratio 0.15× · 2/20
Longevity15 years trading (max 15) · 15/15
Filing complianceAll filings up to date · 15/15
Going concern doubt -10
Show leaderboard
1Charles River U.K. Limited
90
2Werfen Limited
90
3Biopharma Process Systems Limited
90
4Theradex (Europe) Limited
90
5Spicer Consulting Limited
90
6Exmoor Pharma Concepts Limited
90
7Ubc Late Stage (Uk) Limited
90
8Wuxi Apptec Uk Ltd
90
9Cenobiologics Ltd
90
10Ccm Technologies Limited
90
1670Champions Oncology Uk Limited
47
How is this score calculated?
Financial strength12/25 pts

Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.

Employees3/15 pts

Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.

Liquidity2/20 pts

Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.

Longevity15/15 pts

One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.

Filing compliance15/15 pts

Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.

Risk deductions

Going concern doubt: -10 pts

Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.

Going Concern Doubt

we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the directors with respect to going concern are d

Key FinancialsYear ending 30/04/2025

Turnover

£1.8M

Annual revenue

Net Worth

£149

Balance sheet strength

Cash

£66k

Cash in the bank

Net Current Assets

-£571k

Working capital

Current Assets

£101k

Current Liabilities

£672k

Debtors

£35k

Cost of Sales

£306k

Gross Profit

£1.5M

Admin Expenses

£293k

Operating Profit

-£64

0avg. employees-12

Balance Sheet

Assets less current liabilities-£571k
Prepared with IRIS Accounts Production

EstimatesDerived

YearCurrent Ratio
20250.15
20240.12

Derived from filed accounts. Not audited figures.